Vincent T. Ma, MD is an Associate Professor at the University of Wisconsin School of Medicine and Public Health. He is a faculty member in the Division of Hematology, Medical Oncology and Palliative Care within the Department of Medicine and a faculty affiliate of the Department of Dermatology. He is the Immuno-Oncology Therapeutics Lead in the Early Phase Therapeutics Program and Co-Leader of the Melanoma/Advanced Cutaneous Malignancy Disease Oriented Team at the UW Carbone Cancer Center. He also serves as Co-Chair of the Big Ten Cancer Research Consortium Melanoma/Cutaneous Oncology Clinical Trial Working Group.
Dr. Ma received his medical degree from the University of Nevada School of Medicine in Reno, NV. His postgraduate training included a residency at the University of Michigan Health System in Ann Arbor, MI and a Hematology/Oncology Fellowship at the University of Michigan Rogel Cancer Center.
Dr. Ma’s research focuses on optimizing therapeutic strategies for melanoma and other advanced cutaneous malignancies, with an emphasis on drug development involving immunotherapies, molecularly targeted agents, and peripheral blood biomarker discovery. He also has a research interest in the recognition and management of immune-related adverse events associated with immune checkpoint inhibitor (ICI) therapy and is a co-founder of the UW ICI Toxicity Initiative Working Group.
Vincent T. Ma, MD is an Associate Professor at the University of Wisconsin School of Medicine and Public Health. He is a faculty member in the Division of Hematology, Medical Oncology and Palliative Care within the Department of Medicine and a faculty affiliate of the Department of Dermatology. He is the Immuno-Oncology Therapeutics Lead in the Early Phase Therapeutics Program and Co-Leader of the Melanoma/Advanced Cutaneous Malignancy Disease Oriented Team at the UW Carbone Cancer Center. He also serves as Co-Chair of the Big Ten Cancer Research Consortium Melanoma/Cutaneous Oncology Clinical Trial Working Group.
Dr. Ma received his medical degree from the University of Nevada School of Medicine in Reno, NV. His postgraduate training included a residency at the University of Michigan Health System in Ann Arbor, MI and a Hematology/Oncology Fellowship at the University of Michigan Rogel Cancer Center.
Dr. Ma’s research focuses on optimizing therapeutic strategies for melanoma and other advanced cutaneous malignancies, with an emphasis on drug development involving immunotherapies, molecularly targeted agents, and peripheral blood biomarker discovery. He also has a research interest in the recognition and management of immune-related adverse events associated with immune checkpoint inhibitor (ICI) therapy and is a co-founder of the UW ICI Toxicity Initiative Working Group.